Tysabri-associated PML in MS: better survival rates

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Tysabri-associated PML in MS: better survival rates

Postby MSUK » Thu May 19, 2011 12:24 am

Tysabri-associated PML in MS: better survival rates than other patient types

Image

A follow-up study of 35 MS patients with Tysabri-associated progressive multifocal leukoencephalopathy provides a somewhat encouraging survival rate of about 70%.

This percentage is more than twice the quoted survival rate of other patient types with PML (eg, those with HIV infection or following transplantation), and the authors speculate that the improved survival in Tysabri-related cases may be due (partially) to the ability to reconstitute the immune system more easily in these cases.

Factors that appear ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2144
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Postby sou » Thu May 19, 2011 1:54 am

Is this for good or for bad? Am I the only one who wouldn't want to survive after getting PML?
Shortest joke: "We may not be able to cure MS but we can manage its symptoms."
User avatar
sou
Family Elder
 
Posts: 582
Joined: Sat Dec 20, 2008 4:00 pm
Location: Greece

Postby euphoniaa » Thu May 19, 2011 3:20 am

sou wrote:Is this for good or for bad? Am I the only one who wouldn't want to survive after getting PML?


I'm with you, sou.
Dx'd with MS & HNPP (hereditary peripheral neuropathy) 7/03 but must have had MS for 30 yrs before that. I've never taken meds for MS except 1 yr experiment on LDN. (I found diet, exercise, sleep, humor, music help me the most.)
User avatar
euphoniaa
Family Elder
 
Posts: 687
Joined: Sat Jul 15, 2006 3:00 pm
Location: midwest U.S.

Re: Tysabri-associated PML in MS: better survival rates

Postby HarryZ » Thu May 19, 2011 6:49 am

The authors, 3 of whom work for Biogen Idec, the maker of Tysabri, admit that one major deficiency of their follow-up report is the lack of long-term data.


The study was done to try and improve the marketing/sales of Tysabri. Ever since the drug was first approved, Biogen has continually tried to minimize the danger of PML. After all, PML risk is bad for sales and with the orals starting to appear. the competition noose is tightening.

Harry
User avatar
HarryZ
Family Elder
 
Posts: 2557
Joined: Tue May 25, 2004 3:00 pm
Location: London, ON, Canada


Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service